Loading…
Reported covered position: Amy Efantis, L.D., Rep. Artur Davis
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Source: Senate LDA
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Medicare Access and CHIP Reauthorization Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015.
Medicare Access and CHIP Reauthorization Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015; 21st Century Cures.
Confidential Informant Accountability Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Confidential Informant Accountability Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Combination Drug Development Incentive Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
MODDERN Cures Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
Lake Tahoe Restoration Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; Patent Trolls (H.R. 3390 - "Innovation Act")
Drug Quality and Security Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Illegal Compounding, ADUFA Reauthorization (H.R. 3204; S. 622; H.R. 6432)
Lake Tahoe Restoration Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; Patent Trolls (H.R. 3390)
Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Illegal Compounding, ADUFA Reauthorization (H.R. 3204; S. 622; H.R. 6432)
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Preserve Access to Affordable Generics Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Stop Oxy Abuse Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)
Stop Oxy Abuse Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)
Stop Oxy Abuse Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)
Commercial Motor Vehicle Advanced Safety Technology Tax Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369
Commercial Motor Vehicle Advanced Safety Technology Tax Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369
Commercial Motor Vehicle Advanced Safety Technology Tax Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369; Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act)
Commercial Motor Vehicle Advanced Safety Technology Tax Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill -- Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act); False Marketing (H.R. 4954)
Commercial Motor Vehicle Advanced Safety Technology Tax Act of 2011
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369; Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act)
To amend title 38, United States Code, to require judges of the United States Court of Appeals for Veterans Claims to reside within fifty miles of the District of Columbia, and for other purposes.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
To suspend temporarily the duty on certain compression-ignition internal combustion piston engines.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill -- Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act); False Marketing (H.R. 4954)
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Reform; Patent Settlements; H.R. 1706 and S. 5369
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Reform, Patent Settlements; H.R. 1706 and S. 5369
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent reform; Patent settlements; H.R. 1706 and S. 5369
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Reform, Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Reform, Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent Reform, Patent Settlements; H.R. 1706 and S. 5369
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent reform, Patent settlements; H.R. 1706 and S. 5369
America's Affordable Health Choices Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, H.R. 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S. 1679: Senate HELP and S. 1796: Senate Finance committee drafts); pricing/rebates; importation; coverage; comparative effectiveness; biosimilars; transparency; 340B pricing; Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act
America's Affordable Health Choices Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency; 340B pricing, Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act
Affordable Health Choices Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency; 340B pricing, Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act
Affordable Health Choices Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, H.R. 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S. 1679: Senate HELP and S. 1796: Senate Finance committee drafts); pricing/rebates; importation; coverage; comparative effectiveness; biosimilars; transparency; 340B pricing; Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act
America's Healthy Future Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, H.R. 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S. 1679: Senate HELP and S. 1796: Senate Finance committee drafts); pricing/rebates; importation; coverage; comparative effectiveness; biosimilars; transparency; 340B pricing; Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act
America's Healthy Future Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency; 340B pricing, Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.r. 4213)
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health Reform HR.1 American Recovery and Reinvestment Act focusing on Comparative Effectiveness and Trade President's Budget (see details on page 3) House/Senate Budget - H. Con. Res.85 President's Budget including Medicaid Rebates, Medicare Part D, Follow-on Biologics, Importation, Import Safety, Comparative Effectiveness, Patent Settlements, Intellectual Property Reform and Research Tax Credit.
Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health Reform HR.1 American Recovery and Reinvestment Act focusing on Comparative Effectiveness and Trade President's Budget (see details on page 3) House/Senate Budget - H. Con. Res.85 President's Budget including Medicaid Rebates, Medicare Part D, Follow-on Biologics, Importation, Import Safety, Comparative Effectiveness, Patent Settlements, Intellectual Property Reform and Research Tax Credit.
Safe Drug Disposal Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Pharmaceuticals in the environment - drug take back programs; HR 1191
Safe Drug Disposal Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Pharmaceuticals in the environment - drug take back programs; HR 1191
Employee Free Choice Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Employee Free Choice Act - monitoring status of bill HR 1409 and S 560
Employee Free Choice Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Employee Free Choice Act - monitoring status of bill HR 1409 and S 560
Home Office Deduction Simplification Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
H.R.1509, S.560 - Employee Free Choice Act
Home Office Deduction Simplification Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
H.R.1509, S.560 - Employee Free Choice Act
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent reform, Patent settlements; H.R. 1706 and S. 5369
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.515 - Patent Reform Act H.R.1706 - Patent Settlement bill
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Patent reform, Patent settlements; H.R. 1706 and S. 5369
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.515 - Patent Reform Act H.R.1706 - Patent Settlement bill
Protecting Consumer Access to Generic Drugs Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
patent reform, patent settlements; H.R. 1706 and S.5369
America's Affordable Health Choices Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency
America's Affordable Health Choices Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency
Protecting Employees and Retirees in Business Bankruptcies Act of 2010
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
H.R.4677, Relating to duty suspension of cyclopropylanicotine acid; The Farm Bill (amendments to Lacey Act) Miscellaneous Trade Bill
Protecting Employees and Retirees in Business Bankruptcies Act of 2010
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
H.R.4677, Relating to duty suspension of cyclopropylanicotine acid; The Farm Bill (amendments to Lacey Act) Miscellaneous Trade Bill
American Recovery and Reinvestment Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: (Affordable Health Choices Act), coverage,comparative effectiveness, pricing, rebates, bio-similars; Stimulus bill(s): American Recovery and Reinvestment Act - health IT and comparative effectiveness (HR 1 and S. 1)
Affordable Health Choices Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency
Affordable Health Choices Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency
America's Healthy Future Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency
America's Healthy Future Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency
Patent Reform Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.515 - Patent Reform Act H.R.1706 - Patent Settlement bill
Patent Reform Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.515 - Patent Reform Act H.R.1706 - Patent Settlement bill
Employee Free Choice Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Employee Free Choice Act - monitoring status of bill HR 1409 and S 560
Employee Free Choice Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
H.R.1509, S.560 - Employee Free Choice Act
Employee Free Choice Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Employee Free Choice Act - monitoring status of bill HR 1409 and S 560
Employee Free Choice Act of 2009
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
H.R.1509, S.560 - Employee Free Choice Act
Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare Part D Pricing S. 2408 & H.R. 4296, Medicare Electronic Medication and Safety Protection Act of 2007 H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Medicare Part D Pricing S.2408 & H.R. 4296, Medicare Electronic Medication and Safety Protection Act of 2007 H.R.6331, Medicare Improvements for Patients and Providers Act of 2008
To suspend temporarily the duty on Cyclopropylaminonicotinic acid.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
H.R.4677, Relating to duty suspension of cyclopropylaminonicotine acid; The Farm Bill (amendments to Lacey Act)
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Average Sales Price; Reimbursement; 21st Century Cures. CMS Rule Blended J Code for Biosimilars; IPAB (Independent Payment Advisory Board).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Transparency - Fair Drug Pricing Act - Baldwin/McCain.
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines).
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Transparency - Fair Drug Pricing Act - Baldwin/McCain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal and Transparency.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Cost Sharing (Preserving Access to Medicines).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Average Sales Price; Reimbursement; 21st Century Cures.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; Children Health Insurance Program Act of 2015; 21st Century Cures.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015; 21st Century Cures.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Food and Drug Administration Proposed Changes Being Effected Labeling Rule; 21st Century Cures Proposal.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference.
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Cost Sharing (Preserving Access to Medicines); "Hard to Obtain," Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implmentation]; Food and Drug Administration Proposed CBE Labeling Rule; 21st Century Cures Proposal
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Food and Drug Administration Proposed CBE Labeling Rule
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Cost Sharing (Preserving Access to Medicines); CMS Proposed Rule (Protected Classes, etc.); "Hard to Obtain", Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges
Cost Sharing (Preserving Access to Medicines); CMS Proposed Rule (Protected Classes, etc.); "Hard to Obtain"; Risk Evaluation and Mitigation Strategies (REMS); Healthcare Exchanges
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference
Illegal Compounding of Animal Drugs
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importationi; Non Interference
Healthcare Exchanges; Protected Classes; CMS Rule
Illegal Compounding of Animal Drugs
Average Sales Price; Reimbursement
Illegal Compounding, ADUFA Reauthorization (H.R. 3204; S. 622; H.R. 6432)
Healthcare Exchanges; Protected Classes
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain Security
Food and Drug Administration Safety & Innovation Act (FDASIA) - Updates
Shortages; Supply Chain Security; Risk Evaluatioin and Mitigation Strategies (REMS); Compounding
Patent Settlements
Shortages; Supply Chain Security; Risk Evaluation and Mitigation Strategies (REMs); Compounding
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain Security; Patent Settlements
Illegal Compounding
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff; Importation; Non Interference; Supply Chain Security; Patent Settlements
Patent Settlements
Illegal Compounding
Gain Act; Shortages; Supply Chain Security; Best Pharmaceuticals for Children Act/Pediatric Research Equity Act Reauthorization; Risk Evaluation and Mitigation Strategies (REMS); Generic Drug User Fee Act; Prescription Drug User Fee Act
Drug Shortages; The Preserving Access to Life Saving Medicines Act (S. 296)
Patent Settlements
Drug Shortages; The Preserving Access to Life Saving Medicines Act (S. 296)
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Pard D
Patent Settlements
Illegal Compounding
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
Drug Shortages; The Preserving Access to Life Savings Medicines Act (S. 296)
Drug Shortages; The Preserving Access to Life Savings Medicines Act (S. 296)
Patent Settlements; H.R. 1706 and S. 5369
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Pard D/Debt Ceiling
Drug Shortages; The Preserving Access to Life Savings Medicines Act (S. 296)
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Pard D/Debt Ceiling
Patent Settlements; H.R. 1706 and S. 5369
Patent Settlements; H.R. 1706 and S. 5369; Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act)
Reauthorization of the Prescription Drug User Fee Act; Drug Safety
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D/Debt Ceiling
Patent Settlements; H.R. 1706 and S. 5369; Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act)
Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D
Reauthorization of the Prescription Drug User Fee Act; Drug Safety
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill -- Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act); False Marketing (H.R. 4954)
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.r. 4213)
Discussion with Chief Medical Officer -- Afibrulation
Miscellaneous Tariff Bill; relating to the duty suspensionof cyclopropylaminonicotine acid
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
Animal and Plant Health Inspection Service/Center for Veterinary Biologics; veterinary labeling issues
340B (Medicaid) Expansion
Medicare Part D preservation in health reform Rebates, Medicare, Medicaid and Medicaid Expansion in health reform 340B pricing
Health care reform: America's Affordable Health Choices Act, H.R. 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S. 1679: Senate HELP and S. 1796: Senate Finance committee drafts); pricing/rebates; importation; coverage; comparative effectiveness; biosimilars; transparency; 340B pricing; Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act
Health care reform; Patient Protection and Affordable Care Act implementation - pricing/rebates, importation, coverage, comparative effectiveness; biosimilars, transparency; 340B pricing, Independent Patient Advisory Board
Reauthorization of the Prescription Drug User Fee Act; Drug Safety
Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate
Farm Bill, Animal and Plant Health Inspection Service/Center for Veterinary Biologics, veterinary labeling issues
Health care reform; Patient Protection and Affordable Care Act implementation - pricing/rebates, importation, coverage, comparative effectiveness; biosimilars, transparency; 340B pricing, Independent Patient Advisory Board
Reauthorization of the Prescription Drug User Fee Act; Drug Safety
Health care reform: Patient Protection and Affordable Care Act implementation - pricing/rebates, importation, coverage, comparative effectiveness; biosimilars, transparency; 340B pricing, Independent Patient Advisory Board; Prescription Drug User Fee Reauthorization
Farm Bill, Animal and Plant Health Inspection Service/Center for Veterinary Biologics, veterinary labeling issues
Miscellaneous Tariff Bill; relating to the duty suspension of cyclopropylaminonicotine acid
Patent Reform, Patent Settlements; H.R. 1706 and S. 5369
Health care reform: Patient Protection and Affordable Care Act implementation - pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency; 340B pricing, Independent Patient Advisory Board; Prescription Drug User Free Act Reauthorization
Animal and Plant Health Inspection Service / Center for Veterinary Biologics, veterinary labeling issues
340B (Medicaid) Expansion
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
Supplemental Appropriations Bill - patent settlements (no bill number at this stage)
Patent reform, Patent settlements; H.R. 1706 and S. 5369
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency; 340B pricing, Independent Patient Advisory Board; PPACA - Patient Protection and Affordable Care Act
Employee Free Choice Act - monitoring status of bill HR 1409 and S 560
Miscellaneous Tariff Bill; relating to the duty suspension of cyclopropylaminonicotine acid
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency
Health care reform: America's Affordable Health Choices Act, HR 3200 (Education and Labor, Ways and Means, House Energy and Commerce committee drafts), Affordable Health Choices Act, and America's Healthy Future Act (S 1679: Senate HELP and S 1796: Senate Finance committee drafts); pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency
Miscellaneous Trade bill; relating to the duty suspension of cyclopropylaminonicotine acid
Health care reform: (Affordable Health Choices Act), coverage,comparative effectiveness, pricing, rebates, bio-similars; Stimulus bill(s): American Recovery and Reinvestment Act - health IT and comparative effectiveness (HR 1 and S. 1)
patent reform, patent settlements; H.R. 1706 and S.5369
pharmaceuticals in the environment
H.R.1509, S.560 - Employee Free Choice Act
S.515 - Patent Reform Act H.R.1706 - Patent Settlement bill
H.R.1 American Recovery and Reinvestment Act focusing on Comparative Effectiveness and Trade.
S.515 - Patent Reform Act H.R.1706 - Patent Settlement bill
H.R.1509, S.560 - Employee Free Choice Act
H.R.1 American Recovery and Reinvestment Act focusing on Comparative Effectiveness and Trade.
H.R.4677, Relating to duty suspension of cyclopropylaminonicotine acid; The Farm Bill (amendments to Lacey Act)
Protocol Amending the Convention Between the United States of America and Canada with Respect to Taxes on Income and on Capital (Treaty Doc. 110-15); The Bailout (R&D Tax Credit)
Medicare Part D Pricing S.2408 & H.R. 4296, Medicare Electronic Medication and Safety Protection Act of 2007 H.R.6331, Medicare Improvements for Patients and Providers Act of 2008
Medicare Part D Pricing S. 2408 & H.R. 4296, Medicare Electronic Medication and Safety Protection Act of 2007 H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Average Sales Price; Reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Average Sales Price; Reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Average Sales Price; Reimbursement
Food and Drug Administration Safety & Innovation Act (FDASIA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent Settlements; Patent Trolls (H.R. 3390 - "Innovation Act")
Food and Drug Administration Safety & Innovationi Act (FDASIA) - Updates/Implementation
Average Sales Price; Reimbursement
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference; Supply Chain (H.R. 2775)
Patent Settlements; Patent Trolls (H.R. 3390)
Food and Drug Administration Safety & Innovation Act (FDASIA) - Updates
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Illegal Compounding
Patent Settlements
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Illegal Compounding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Gain Act; Shortages; Supply Chain Security; Risk Evaluation and Mitigation Strategies (REMs)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent Settlements
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Illegal Compounding
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D; Fiscal Cliff
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Gain Act; Shortages; Supply Chain Security; Best Pharmaceuticals for Children Act/Pediatric Research Equity Act Reauthorization; Risk Evaluation and Mitigation Strategies (REMS); Generic Drug User Fee Act; Prescription Drug User Fee Act
Drug Shortages; The Preserving Access to Life Savings Medicines Act (s. 296)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Health Care Reform; Patent and Affordable Care Act implementation - pricing/rebates; importation; coverage; Independent Patient Advisory Board
Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health care reform; Patent and Affordable Care Act implementation - pricing/rebates; importation; coverage; Independent Patient Advisory Board; drug shortages; The Preserving Access to Life Saving Medicines Act (S.296)
Reauthorization of the Prescription Drug User Fee Act; Drug Safety
Animal and Plant Health Inspection Service/Center for Veterinary Biologics; veterinary labeling issues; Proposed Cephlosporin Ban -- Food and Drug Administration (FDA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health care reform; Patient Protection and Affordable Care Act implementation - pricing/rebates; importation; coverage; comparative effectiveness; Independent Patient Advisory Board; drug shortages; The Preserving Access to Life Saving Medicines Act (S. 296)
Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)
Animal and Plant Health Inspection Service/Center for Veterinary Biologics; veterinary labeling issues; Proposed Cephlosporin Ban - Food and Drug Administration (FDA)
340B (Medicaid) Expansion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent Reform, Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate
Farm Bill, Animal and Plant Inspection Service/Center for Veterinary Biologics, veterinary labeling issues
340B (Medicaid) Expansion
Reauthorization of the Prescription Drug User Fee Act; Drug Safety
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Patent Reform; Patent Settlements; H.R. 1706 and S. 5369
Health care reform; Patient Protection and Affordable Care Act implementation - pricing/rebates; importation; coverage; comparative effectiveness; biosimilars; transparency; 340B pricing; Independent Patient Advisory Board; Prescription Drug User Fee Act Reauthorization
Supplimentatl Appropriations Bill - patent settlements (no bill number at this stage)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APHIS/CVB issues; veterinary labeling issues
Patent reform; Patent settlements; H.R. 1706 and S. 5369
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Farm Bill, Animal and Plant Health Inspection Service/Center for Veterinary Biologics, veterinary labeling issues
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
340B (Medicaid) Expansion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate
340B (Medicaid) Expansion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent Reform, Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill - Senate
340B (Medicaid) Expansion
Reauthorization of the Prescription Drug User Fee Act; Drug Safety
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Supplemental Appropriations Bill - patent settlements (no bill number at this stage)
Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)
340B (Medicaid) Expansion
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health care reform: Patient Protection and Affordable Care Act implementation - pricing/rebates, importation, coverage, comparative effectiveness, biosimilars, transparency; 340B pricing, Independent Patient Advisory Board; Prescription Drug User Free Act Reauthorization
Animal and Plant Health Inspection Service / Center for Veterinary Biologics, veterinary labeling issues
Patent Reform, Patent Settlements; H.R. 1706 and S. 5369
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APHIS/CVB issues, veterinary labeling issues
Medicare Part D preservation in health reform Rebates, Miedicare, Medicaid and Medicaid Expansion in health reform 340B pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Medicare Part D preservation in health reform Rebates, Medicare, Medicaid and Medicaid expansion in health reform
Pharmaceuticals in the environment - drug take back programs; HR 1191
Patent reform, Patent settlements; H.R. 1706 and S. 5369
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Pharmaceuticals in the environment - drug take back programs; HR 1191
Employee Free Choice Act - monitoring status of bill HR 1409 and S 560
Patent reform, Patent settlements; H.R. 1706 and S. 5369
Medicare Part D preservation in health reform Rebates, Medicare, Medicaid and Medicaid expansion in health reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Employee Free Choice Act
Miscellaneous Trade bill; relating to the duty suspension of cyclopropylaminonicotine acid; The Farm bill (amendment to Lacey Act)
Medicare Part D preservation in health reform Rebates, Medicare, Medicaid and Medicaid expansion in health reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health Reform HR.1 American Recovery and Reinvestment Act focusing on Comparative Effectiveness and Trade President's Budget (see details on page 3) House/Senate Budget - H. Con. Res.85 President's Budget including Medicaid Rebates, Medicare Part D, Follow-on Biologics, Importation, Import Safety, Comparative Effectiveness, Patent Settlements, Intellectual Property Reform and Research Tax Credit.
H.R.4677, Relating to duty suspension of cyclopropylanicotine acid; The Farm Bill (amendments to Lacey Act) Miscellaneous Trade Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Health Reform HR.1 American Recovery and Reinvestment Act focusing on Comparative Effectiveness and Trade President's Budget (see details on page 3) House/Senate Budget - H. Con. Res.85 President's Budget including Medicaid Rebates, Medicare Part D, Follow-on Biologics, Importation, Import Safety, Comparative Effectiveness, Patent Settlements, Intellectual Property Reform and Research Tax Credit.
H.R.4677, Relating to duty suspension of cyclopropylanicotine acid; The Farm Bill (amendments to Lacey Act) Miscellaneous Trade Bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE